In a phase II randomized study of 275 patients in the adjuvant setting, a DC vaccine targeting the E75 peptide derived from the HER2 protein was tested with trastuzumab in breast cancer patients with low HER2 expression65. This evidence concerns the gene ERBB2 and breast cancer.